Key Takeaways LLY beat Q2 estimates with EPS of $6.31 and revenues of$15.56B, driven by Mounjaro and Zepbound sales.Mounjaro and Zepbound sales rose sharply, aided by global launches and ramped-up supply.Shares fell after orforglipron's 12.4% weight loss missed investor expectations in the obesity trial.Eli Lilly and Company (LLY) reported second-quarter 2025 adjusted earnings per share (“EPS”) of $6.31, which beat the Zacks Consensus Estimate of$5.61 per share. Earnings rose 61% year over year.Revenues o ...